title: Alginate lyase and ciprofloxacin co-immobilization on biopolymeric microspheres for cystic fibrosis treatment.
abstract: A new formulation is described based on biopolymeric microspheres containing alginate lyase (AL) and ciprofloxacin (Cip) for sustainable oral delivery in CF patients. Alginate (ALG) and high-methoxyl pectin (HMP) are selected as the biopolymers to develop a composite matrix. ALG microspheres coated with HMP and ALG-HMP blend are gelled in water/organic solvents mixtures, obtaining Cip encapsulations from 46.0 to 100.0%. ALG-HMP shows a Cip sustainable release profile and is able to encapsulate 90.0% of AL, showing 76.0% enzyme activity after release under simulated intestinal conditions. The developed system is a promising delivery carrier to treat chronic infection of Pseudomonas aeruginosa and to reduce the viscoelasticity of the mucus accumulated into intestine of CF patients.
authors: Nanobiomaterials Laboratory, Applied Biotechnology Institute (CINDEFI, UNLP-CONICET CCT La Plata) - School of Sciences, Universidad Nacional de La Plata, Calle 47 y 115, CP 1900, La Plata, Argentina.
authors: German A
authors: GA
authors: Islan
authors: Valeria E
authors: VE
authors: Bosio
authors: Guillermo R
authors: GR
authors: Castro
mesh_terms: D001704:Biopolymers / Q000737:chemistry*; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004800:Enzymes, Immobilized / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D010368:Pectins / Q000737:chemistry; D011133:Polysaccharide-Lyases / Q000378:metabolism*; D019946:Propylene Glycol / Q000737:chemistry; D012997:Solvents
chemical_list: D001704:Biopolymers; D004800:Enzymes, Immobilized; D012997:Solvents; D002939:Ciprofloxacin; D019946:Propylene Glycol; D010368:Pectins; D011133:Polysaccharide-Lyases; C016158:poly(beta-D-mannuronate) lyase
keywords: alginate lyase; biopolymers; ciprofloxacin; cystic fibrosis; drug delivery